IRIS
RIMASSA, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.807
EU - Europa 1.668
AS - Asia 425
AF - Africa 209
SA - Sud America 18
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 11
Totale 9.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.723
FI - Finlandia 437
IE - Irlanda 331
CN - Cina 250
IT - Italia 238
NG - Nigeria 205
DE - Germania 185
FR - Francia 147
NL - Olanda 95
CA - Canada 83
SE - Svezia 72
GB - Regno Unito 59
IN - India 46
TR - Turchia 40
BE - Belgio 30
IL - Israele 27
RU - Federazione Russa 22
HK - Hong Kong 14
JP - Giappone 13
AU - Australia 11
CL - Cile 11
IR - Iran 10
SG - Singapore 10
EU - Europa 8
UA - Ucraina 8
PL - Polonia 6
AT - Austria 5
CH - Svizzera 5
RO - Romania 5
BD - Bangladesh 4
ES - Italia 4
GR - Grecia 4
PT - Portogallo 4
A2 - ???statistics.table.value.countryCode.A2??? 3
ID - Indonesia 3
ML - Mali 3
VN - Vietnam 3
BR - Brasile 2
HR - Croazia 2
KR - Corea 2
NO - Norvegia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BG - Bulgaria 1
CO - Colombia 1
IM - Isola di Man 1
KZ - Kazakistan 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PE - Perù 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 9.150
Salva come PNG Salva come JPEG
Città #
Wilmington 1.287
Chandler 1.285
San Mateo 477
Helsinki 437
Ann Arbor 394
Dublin 330
Lawrence 253
Princeton 252
Leawood 232
New York 231
Benin City 205
Boardman 202
Shanghai 201
Ashburn 197
Paris 136
Fairfield 108
Woodbridge 108
Milan 96
Amsterdam 90
Toronto 61
London 54
Phoenix 51
San Diego 42
Kocaeli 39
Abbiategrasso 31
Redwood City 31
Pune 30
Brussels 28
Norwalk 27
Los Angeles 25
Seattle 24
Falkenstein 16
Redmond 15
Andover 13
Monmouth Junction 13
Moscow 13
St Louis 12
Hanover 10
Santa Clara 10
Montreal 7
Falls Church 6
Montréal 6
Tappahannock 6
Winnipeg 6
Des Moines 5
Frankfurt am Main 5
Manassas 5
Roubaix 5
Sacramento 5
Shenzhen 5
Umeda 5
Clearwater 4
Florence 4
Genoa 4
Houston 4
Jinan 4
Porto 4
Raleigh 4
Rome 4
Tai Kok Tsui 4
Bamako 3
Beijing 3
Cambridge 3
Chicago 3
Freiburg im Breisgau 3
Gurgaon 3
Ho Chi Minh City 3
Lausanne 3
Nanjing 3
Tokyo 3
Verona 3
Alexandria 2
Apo 2
Ariano nel Polesine 2
Central District 2
Changzhou 2
Chengdu 2
Cinisello Balsamo 2
Dhaka 2
Eden Prairie 2
Ferrara 2
Gdynia 2
Gunzenhausen 2
Henderson 2
Jakarta 2
Kemerovo 2
La Canada Flintridge 2
Melbourne 2
Milwaukee 2
Monza 2
Palermo 2
Perth 2
Providence 2
Singapore 2
São Paulo 2
Warsaw 2
Zagreb 2
Zhuhai 2
Acireale 1
Almaty 1
Totale 7.257
Salva come PNG Salva come JPEG
Nome #
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 69
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 67
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 66
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 64
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 60
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 60
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 58
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 57
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 57
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 57
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 56
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 56
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 55
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 54
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 54
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 54
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 54
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 54
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 53
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 53
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 53
COVID-19 and liver cancer clinical trials: not everything is lost 52
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 52
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 52
Biomarkers in Hepatocellular Carcinoma-Letter 51
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 51
Prognostic value of the immune-related transcriptome in biliary tract cancers 51
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 51
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 51
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 51
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 51
Cabozantinib for the treatment of hepatocellular carcinoma 50
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 50
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 50
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 49
Characterisation of the immune-related transcriptome in resected biliary tract cancers 49
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 49
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 48
Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer 48
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 48
Phase III trial comparing 3 to 6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial 48
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 48
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 47
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 47
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 47
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 46
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 46
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 46
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 46
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 46
Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle 46
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 46
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 46
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 45
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 45
Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma 45
Reply to Y. Pointreau et al 45
Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer 45
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 45
Nurses and health care assistants: Evaluation of attitude towards the care of patients who are terminally ill with cancer. 44
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 44
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 44
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 44
F-18-FDG-PET (PET) and contrast-enhanced CT-scan (CT) in the evaluation of liver metastases from colorectal cancer after chemotherapy 44
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 44
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 44
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 44
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 44
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 44
Effectiveness of precautionary chemotherapy in gastric cancer 43
Shaping the landscape of immune oncology in hepatocellular carcinoma 43
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 43
Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer 43
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 43
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma 43
Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells 43
Hepatotoxicity of immune check point inhibitors: Approach and management 43
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 42
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 42
Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane 42
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 42
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 42
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 42
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 42
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients 41
Nicotinamide Phosphoribosyltransferase (NAMPT) acts as a metabolic gate for mobilization of myeloid-derived suppressor cells 41
Phase 2 study of tivantinib and cetuximab in KRAS wild-type metastatic colorectal cancer patients with acquired resistance to EGFR inhibitors and emergence of MET overexpression: lesson learned for future trials with EGFR/MET dual inhibition 41
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 41
Combined PD-1/VEGFR blockade: a new era of treatment for hepatocellular cancer 41
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 41
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 40
The present and the future landscape of treatment of advanced HCC. 40
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 40
Caregiver training for a therapeutic alliance in palliative home care. 40
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 40
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review 40
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 40
Tivantinib for hepatocellular carcinoma 39
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma 39
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 39
Totale 4.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 0 0 0 3 21
2020/20212.514 21 24 21 12 104 768 355 158 455 314 33 249
2021/20221.504 61 43 20 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20241.749 161 251 455 89 76 341 161 127 36 52 0 0
Totale 9.577